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Abstract: Background: Endometriosis is a widespread multifactorial disease in which environmental,
genetic, and epigenetic factors contribute to the phenotype. Single Nucleotide Polymorphisms (SNPs)
in genes implicated in pivotal molecular mechanisms have been investigated as susceptible risk
factors in distinct populations. Among these, Toll-like receptor 4 (TLR4) represents a good candidate
due to its role in the immune/inflammatory response and endometriosis pathogenesis. Methods:
The TRL4 gene T399I SNP (C/T transition, rs4986791) was investigated in 236 Italian endometriosis
patients and 150 controls by using the PCR-RFLP method. One-tailed Fisher’s exact test was used
to compare differences between categorical variables. T399I genotype distribution was evaluated
for Hardy–Weinberg equilibrium in both groups using the Chi-squared test for given probabilities.
Results: Fisher’s exact test comparing C and T allele frequencies showed a difference in the frequency
of T alleles between patients and controls (OR = 1.96, 95% confidence interval 0.91–4.23; p-value =
0.0552). Genotype frequencies did not show any significant difference between patients and controls.
The homozygous TT genotype was observed in 2% of endometriosis women and not in controls.
Conclusions: Our results show that the TLR4 rs4986791 T variant may be considered a genetic risk
factor for endometriosis in Italian women. More extensive studies in other populations are needed to
confirm this result.
Keywords: endometriosis; TLR4; T399I polymorphism
1. Introduction
Endometriosis is a gynecological condition characterized by the presence of ectopic endometrial
tissue (endometrial glands and stroma) predominantly in the pelvic peritoneum, ovarian and
rectovaginal septum and, more rarely, in the diaphragmatic, pleural, and pericardial spaces [1].
The disease is a common health problem affecting up to 10% of women in reproductive age [2].
The phenotypic manifestations vary from a mild disease with peritoneal involvement to a severe
form with both affected ovaries, infiltrating lesions and extensive adhesions [3]. Symptoms are often
accompanied by chronic pelvic pain, dysmenorrhea, dyspareunia and reduced fertility [4]. Intensity
of pain symptoms varies significantly among patients, not always correlated with the severity of
endometriosis. In particular, in women with chronic pelvic pain, psychological consequences may
arise, also influencing the perception of pain [5,6]. Endometriosis is a multifactorial disorder in which
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environmental, pro-inflammatory, genetic, and epigenetic factors may trigger the specific clinical
signs [7].
Twin studies estimated endometriosis heritability at approximately 50% [8], however, its pathogenesis
and pathophysiology have not been fully elucidated so far, although many studies have been conducted
to investigate the innate and acquired risk factors.
Many endometriosis susceptibility genes have been detected by Genome Wide Association Studies
(GWAS) [9]. GWAS, however, cannot identify genetic specific associations in different populations [10],
since there are differences in terms of genetic susceptibility and disease manifestations, as demonstrated
by genetic association studies in selective populations [11].
The role of Toll-like receptors (TLRs), which regulate the activation of immune response and
inflammation pathways, has been largely investigated in endometriosis [12]. Altered Toll-like receptor
4 (TLR4) expression or function in endometrium was demonstrated in many in vitro and in vivo
studies [13–16]. TLR4 is expressed in macrophages, endometrial and endometriotic epithelial cells as
well as in stromal cells [17], and it is implicated in the response to exogenous (i.e., Lipopolysaccharide,
LPS) [18] or endogenous ligands (i.e., low-density lipoprotein and heat shock proteins) [19]. Recent
studies pointed out the involvement of the LPS/TLR4 cascade in the growth regulation in endometriosis
tissues [17], since LPS/TLR4 dysfunction may impair the correct mechanism of immune response and
favor the onset and progression of the disease. Most studies in different infectious, inflammatory,
and autoimmune diseases have focused on two Single Nucleotide Polymorphisms (SNPs) (D299G,
rs4986790 and T399I, rs4986791) within the TLR4 gene (OMIM * 603030), which have been demonstrated
to be (or not) susceptible genetic factors in different populations [20]. The first SNP is an A/G transition
causing an Asp/Gly polymorphism at amino acid 299 (D299G; rs4986790) and the second one is a C/T
transition causing a Thr/Ile polymorphism at amino acid 399 (T399I; rs4986791). The TLR4 D299G
SNP has been previously investigated in endometriosis, in Indian [21] and Brazilian [22] cohorts of
women. The TRL4 T399I polymorphism, however, has never been investigated in endometriosis
patients. The aim of the present study was to clarify the role of the TRL4 T399I polymorphism in
this complex genetic scenario, by performing a case-control study comprising an Italian cohort of
236 patients affected by endometriosis and 150 healthy controls.
2. Materials and Methods
2.1. Patients and Controls
A total of 236 Italian unrelated patients were recruited from the Department of Maternal and
Child Health and Urology of Policlinico Umberto I Hospital, Sapienza University of Rome, and were
included in the study. All were affected by endometriosis with diagnosis confirmed by laparoscopy
and histologic analysis. Stages of disease were classified according to the revised American Society for
Reproductive Medicine (rASRM) classification [23]. In the study group, dyspareunia, dysmenorrhea
and pelvic pain were investigated using VAS and assigning a score based on the intensity perceived by
the patient (0: no pain; 1–4: mild; 5–7: moderate; 8–10: severe). As controls, 150 healthy women from
the same ethnic origin were enrolled in the study. Pelvic examination and transvaginal ultrasound
were performed and resulted normal. Laparoscopy was not performed systematically but, when
available, resulted normal in these women.
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved (reference code 3545/2015) by the Ethics Committee of The Institutional Review Board of
Policlinico Umberto I Hospital.
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2.2. DNA Extraction and T399I Genotyping
Genomic DNA was extracted from 5 mL of peripheral whole-venous blood using a salting
out procedure, as previously described [24], and quantified by NanoDrop 2000 (Thermo Fisher
Scientific, Inc., Waltham, MA, USA). T399I polymorphism (+1196C/T transition; rs4986791) was typed
by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
Briefly, the DNA region comprehending the polymorphism was amplified by PCR by using the
TLR4 T399I-forward: 5′-GGTTGCTGTTCTCAAAGTGATTTTGGGAGAA-3′ and TLR4 T399I-reverse:
5′-ACCTGAAGACTGGAGAGTGAGTTAAATGCT-3′ primers. Amplifications were carried out in a
final volume of 30 µL including 200 ng of DNA template, primers at 500 nM and 1 U of Taq polymerase
(Invitrogen, Carlsbad, CA, USA). PCR conditions were as follows: denaturation for 4 min at 95 ◦C,
35 cycles of 45 sec at 95 ◦C, 45 sec at 67 ◦C and 90 sec at 72 ◦C, followed by 5 min at 72 ◦C. The specific
amplificated band of 406 bp was digested by a HinfI enzyme (New England Biolabs, Ipswich, MA,
USA), following the manufacturer’s instructions. PCR-RFLP products were separated upon digestion
in 3% NuSieve GTG agarose gels (Lonza Rockland, Rockland, ME, USA) with GelRed Nucleic Acid Gel
Stain (Biotium, Fremont, CA, USA) and visualized under Ultraviolet (UV) light by using a ChemiDoc
XRS analyzer (Bio-Rad, Hercules, CA, USA).
2.3. Statistical Analysis
All statistical analyses were performed with R: A Language and Environment for Statistical
Computing (R Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2019) and
a p-value < 0.05 was considered statistically significant. The Fisher’s exact test was used to compare
differences between categorical variables. Odds ratio (OR) and 95% confidence interval were calculated.
T399I genotype distribution was evaluated for Hardy–Weinberg equilibrium in the control group and
in the patient group by Chi-squared (χ2) test for given probabilities.
3. Results
To investigate whether the TRL4 T399I polymorphism (rs4986791) is associated with endometriosis
in the Italian population, we performed a case-control study, comparing 236 unrelated patients with
150 healthy women. The mean age in the endometriosis group was 41 years ± 9 SD. According to the
Visual Analogue Scale (VAS), severe or moderate dysmenorrhea was respectively present in 50.3%
and 25.1% of women with endometriosis, moderate or severe dyspareunia in 16.2% and 22.0% and
moderate or severe chronic pelvic pain in 15.7% and 14.7%. Only 17.9% of these patients were affected
by infertility. According to the rASRM classification [23], 2.1% of women had stage I endometriosis,
7.2% had stage II, 54.7% had stage III and 36.0% had stage IV. Healthy controls (n = 150) had a mean age
of 35.2 years ± 11 SD and did not present a history of endometriosis nor clinical and ultrasonographic
signs of this disease. A polymerase chain reaction (PCR) amplicon of 406 bp was obtained, which
resulted indigested upon incubation with a HinfI restriction enzyme in the presence of C nucleotide,
whilst was cut in two fragments of 378 and 28 bp when the allele T was present (data not shown).
Frequency of the C allele resulted 94 % among patients and 97 % in controls and the frequency of
the T allele resulted 6% among patients and 3% in controls. The one tailed p-value of the Fisher’s exact
test comparing the frequencies of the two alleles was p = 0.0552, showing a slight statistical evidence of
difference between endometriosis patients and controls. The OR resulted 1.96 (95% confidence interval
0.91–4.23). The frequency of the three different genotypes did not show any significant differences
between patients and controls, however, TT genotype was observed only in women with endometriosis
(2%). Table 1 summarizes the allele and genotype frequencies of the TRL4 T399I polymorphism in
affected and healthy women.
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Table 1. Allele and genotype frequencies of the TLR4 T399I polymorphism in patients with endometriosis
and controls. The genetic model was considered dominant in the hypothesis that the T variant is a risk
factor for the disease.
TLR4 Patients (236) Controls (150)
n % n %
Allele
C 445 (94%) 291 (97%)
T 27 (6%) 9 (3%)
Genotype
CC 213 (90%) 141 (94%)
CT 19 (8%) 9 (6%)
TT 4 (2%) 0 (-)
Dominant model
CT+TT 23 (10%) 9 (6%)
CC 213 (90%) 141 (94%)
In an inheritance model, in which T is the dominant allele and the risk factor for endometriosis,
the prevalence of CT heterozygotes and TT homozygotes, collectively considered, resulted higher
in affected women than controls (10% vs. 6.0%) but this difference was not statistically significant
(Table 1).
The four TT homozygotes, identified in endometriosis patients only, presented advanced stages
of disease according to the rASRM classification [23], two patients in stage III and two in stage IV.
Other details on clinical phenotype including VAS, age, Body Mass Index (BMI), other associated
diseases and infertility are reported in Table 2. Mean age in homozygous patients (TT genotype) was
43.5 years ± 9 SD.
The genotype distribution resulted in Hardy–Weinberg equilibrium (HWE) in controls but not
in patients.
In the control group, the expected frequency of the three genotypes was 94% CC, 6% CT, 0%
TT and in the observed group was 94% CC, 6% CT, 0% TT (χ2 = 0.14348, d.f. = 2, p-value = 0.9308).
The p-value is higher than 0.05, suggesting no deviation of HWE in the control group.
In the endometriosis group, the expected frequency of the three genotypes was 89% CC, 11%
CT, 0% TT, whereas in the observed group was 90% CC, 8% CT, 2% TT (χ2 = 15.179, d.f. = 2,
p-value = 0.0005057).
Therefore, in the endometriosis group a significant deviation from the HWE (p-value = 0.0005057)
was observed, suggesting that differences are not attributed to chance.
Altogether, our results indicate that the presence of the TLR4 rs4986791 T variant may be considered
a genetic risk factor for endometriosis.
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Table 2. Clinical characteristics of patients with TT genotype at TLR4 polymorphism.
Patient ID Age BMI Dyspareunia * Dysmenorrhea * Pelvic Pain * Infertility Associated Diseases Surgery Stage **
1 35 21.1 mild moderate no no no monolateral endometriosic cyst IV
2 54 18.4 no moderate no no Multiple Sclerosis monolateral endometriosic cyst IV
3 37 22.2 severe severe severe no Irritable BowelSyndrome
monolateral endometrioma and
adenomyosis III
4 48 20 mild no no no Gestational Diabetes monolateral endometrioma andperitoneal endometriosis III
* Dyspareunia, dysmenorrhea and pelvic pain were investigated using VAS and assigning a score based on the intensity perceived by the patient (0: no pain; 1–4: mild; 5–7: moderate; 8–10:
severe). ** Stages of disease were classified according to the rASRM classification [23].
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4. Discussion
Endometriosis is an insidious disorder, often labeled as the “missing disease” [25], with an
important diagnostic delay and still lack of resolutive treatments, significantly impacting women’s
daily lives. It represents a chronic disease, inducing pain and psychological involvement, with negative
consequences affecting fertility, sexuality, ability to work, and social and personal relationships [4].
Many women feel that endometriosis controls and limits their lives. Moreover, the need of long-term
treatments and the absence of a definitive cure can be contributing factors. The impact of endometriosis
is worsened by a lack of understanding of the disease’s causes and an increased awareness is needed
in society and in research to elucidate its etiopathogenesis.
As for other multifactorial diseases, symptoms and causes of endometriosis are related to
an aberrant interplay among genetic, epigenetic, and environmental modifications. The study of
genetic backgrounds in different ethnic populations is crucial to better understand these complex
interactions. In the last decade, many gene polymorphisms implicated in different molecular pathways
have emerged as good candidates to be investigated. Considering the increasing evidence of an
inappropriate immunological response in the pathogenesis of several complex disorders, many studies
have been conducted to identify the genetic determinants that can modify the immune system. Among
these, SNPs in the coding and promoter regions of the human TLR4 gene have been demonstrated
to induce a dysregulated TLR4 signaling pathway, this directly correlated to various infectious,
autoimmune, allergic, inflammatory diseases, and lastly, endometriosis [20].
Indeed, TLR4 is essential for the innate immune response and it is composed of three domains:
an extracellular domain mediating LPS recognition and receptor dimerization, a transmembrane
domain and Toll/Interleukin-1 receptor (TIR) domain, which is essential for downstream signal
transduction [26]. For the LPS recognition, the extracellular domain of TLR4 is associated with myeloid
differentiating protein 2 (MD2), forming a complex and conferring LPS responsiveness to TLR4 [27].
Given its importance in pathogen recognition, TRL4 is highly polymorphic even if its structure is
conserved [28]. The extracellular domain shows many sequence variations, such as the D299G and
T399I changes, caused by two nonsynonymous and commonly co-segregating SNPs in Caucasian
populations [29]. D299G change causes LPS hypo-responsiveness and markedly reduced expression of
the protein on the surface of epithelial cells, and T399I change shows a milder LPS-hyporesponsive
phenotype [30]. The combined effect of the two SNPs leads to the most severe LPS hypo-responsiveness
compared to the responses caused by the single alleles [30]. Consequently, a debated question is how
D299G and T399I changes may affect the LPS responsiveness. Preliminary studies have been shown to
affect appropriate interaction with agonist or coreceptor [31] or suppressing activation of transcription
factors [32]. Crystallography showed that the D299G change may locally disrupt the TLR4 structure,
while T399I does not affect the wild type and mutant TLR4 structure [33]. More recent computational
approaches of molecular dynamics show that both polymorphisms may abrogate the stability of the
hexamer complex, leading to a compromised TLR4 signaling [34]. The role of the two TLR4 SNPs
has been largely investigated in many diseases, with genetic association to some infection-related
susceptibility, such as Gram-negative caused diseases and septic shock [35,36] or to inflammatory
diseases susceptibility, such as Crohn’s [37]. Negative studies have been also reported, i.e., in Systemic
Lupus Erythematous [38].
In endometriosis patients, a significant increase in TLR4 mRNA expression in ectopic endometriotic
lesions compared with corresponding eutopic tissue was reported [13]. Hayashi et al. [15] studied
TLR4 expression in endometriosis patients, confirming an increased expression of the TLR4 mRNA
and protein in ectopic endometrium compared to eutopic endometrium. A higher expression of TLR4
mRNA was also observed in the menstrual phase in the eutopic endometrium of healthy women,
probably as a defense mechanism of the uterus. Both menstrual blood and shed endometrium could
be a favorable environment for bacterial infection [15].
The role of the TRL4 D299G polymorphism in determining susceptibility to endometriosis has been
previously investigated in two different cohorts of women affected by endometriosis. The first study
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demonstrated an association between the GG genotype and the G allele and the risk of endometriosis in
an Indian cohort [21]. Authors hypothesized that in women carrying the TLR4 D299G polymorphism,
particularly during the period of menstruation, the retrogradely shed endometrial cells could be
implanted on the peritoneum (in the pouch of Douglas) and favorite the onset of endometriosis [21].
The second study, conducted in a Brazilian cohort, did not show significant differences in
genotypic or allelic frequencies between patients and controls groups, with no individuals carrying
the GG genotype [22]. This discordant finding could be attributed to the different constitution of the
two populations, as the worldwide frequencies of TLR4 polymorphisms show distinct patterns of
distribution considering different populations and ethnic groups [39].
In the present study, we used a case-control approach to assess if TLR4 T399I polymorphism is a
susceptibility factor to endometriosis in Italian women. Our data suggest an association of the T allele
with endometriosis disease, showing a 1.96-fold increased OR when evaluating patients and controls.
Interestingly, homozygous TT genotype was only observed in women with endometriosis, but not in
healthy females, even if the comparison did not result significant. However, considering the frequency
of endometriosis and the Minor Allele Frequency (MAF) of the TLR4 T399I SNP, the lack of significant
association between genotype and endometriosis risk may be due to the relatively low number of
analyzed women, this representing the main limit of the present research. More extensive studies, also
involving other genetic variations in the TLR4 gene as well as replication in larger number of patients
and in different populations, will be needed to confirm our observations. Interrogation of the Genome
Aggregation Database (gnomAD, v.2.1.1), the largest population database to date, in 140,863 available
individuals, T399I shows an overall MAF of 6%, ranging from 1% in Africans to 6% in Europeans
(non-Finnish) and 10% in Finnish. In gnomAD, TT homozygotes are very rare (0.4%). On the contrary,
in our cohort of patients, homozygotes have a frequency of almost 2% vs. 0% in the control group.
The four TT homozygous patients did not show a specific association neither with higher VAS
scores for dyspareunia, dysmenorrhea and pelvic pain, nor with infertility (Table 2). Nonetheless, all
the TT patients presented advanced stages of endometriosis (III and IV, Table 2), this suggesting that
the T399I polymorphism might be involved in the progression and severity of the disease but future
studies and functional analyses are needed to demonstrate our hypothesis.
Table 3 summarizes some details on the genetic relationship between the TLR4 gene and
endometriosis in Indian [21], Brazilian [22] and Italian populations (present research).
Table 3. TLR4 SNPs in endometriosis patients and controls in different populations.
TLR4 SNPs [Ref] EndometriosisGroup Control Group p-Value (χ
2)
Odds Ratio
(Confidence Interval)
rs4986790 A/G [21]
Indian population N = 200 N = 200
Allele frequency A = 89% G = 11% A = 97% G = 3% p < 0.05 OR = 4.48 (95% CI 2.28–8.80)
rs4986790 A/G [22]
Brazilian population n= 100 n= 100
Allele frequency A = 96% G = 4% A = 95% G = 5% ns ns
rs4986791 C/T
present study, Italian population n = 236 n = 150
Allele frequency C = 94% T = 6% C = 97% T = 3% p = 0.0552 OR = 1.96 (95% CI 0.91–4.23)
In previous studies of Italian cohorts of endometriosis patients, environmental factors [40], as well
as different SNPs in other genes were investigated [41–44]. More recently, in a Mediterranean cohort
of patients (Sardinian population), no significant association was observed for three SNPs present in
WNT4, VEZT and FSHB genes (rs7521902, rs10859871 and rs11031006, respectively), which have been
previously identified as risk factors for endometriosis in other populations [45]. Both negative and
positive results are important to shed light on risk factors of this complex disease.
According to our observation, the TLR4 polymorphisms and the related inflammation pathways
seem to be good candidates to further investigations. Many studies have linked genetic variations in
TLR4 with susceptibility to different infectious and inflammatory diseases, with complex interactions
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depending on environmental factors, ethnic backgrounds, and multigenic effects [20], probably
involving different gene networks.
The identification of genetic risk factors in specific populations may better elucidate their effects
and their possible roles in disease prognosis and prevention [46].
To date, in endometriosis patients, diagnosis delays and limited effectiveness of treatments are
well known issues, causing negative impacts on women’s quality of life. In multifactorial diseases
such as endometriosis, the genetic contribution to the phenotype depends on the combination of
alleles, and multiple genetic interactions in different pathways contribute to disease susceptibility and
possibly correlate with specific phenotypes in terms of disease severity, progression and associated
symptoms. Identifying genetic risk factors could improve the management and prevention of physical
and psychological complications of a specific disorder.
In conclusion, our data indicate the association of the TLR4 rs4986791 T allele with endometriosis
in an Italian cohort of women, this supporting the role of genetic variations in the modulation of the
TLR4-mediated immune response in endometriosis disease.
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Abbreviations
SNP Single Nucleotide Polymorphism
TLR4 Toll-like receptor 4
C/T Cytosine to Thymine
PCR-RFLP Polymerase Chain Reaction-Restriction Fragment Length Polymorphism
Thr/Ile Threonine to Isoleucine
T399I Threonine 399 to Isoleucine
OR Odds Ratio
GWAS Genome Wide Association Study
TLRs Toll-like receptors
LPS Lipopolysaccharide
LPS/TLR4 Lipopolysaccharide/Toll-like receptor 4
A/G Adenine to Guanine
Asp/Gly Aspartate to Glycine
D299G Aspartate 299 to Glycine
SD Standard Deviation
bp base pair
HWE Hardy–Weinberg equilibrium
ASRM American Society for Reproductive Medicine
BMI Body Mass Index
VAS Visual Analogue Scale
TIR Toll/Interleukin-1 receptor
MD2 Myeloid Differentiating protein 2
MAF Minor Allele Frequency
gnomAD Genome Aggregation Database
WNT4 Wingless-Type MMTV Integration Site Family Member 4 gene
VEZT Vezatin gene
FSHB Follicle-Stimulating Hormone Beta Polypeptide gene
UV Ultraviolet
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